Trump says Iran war "close to over" amid hopes for more negotiations
VivoSim Labs Inc. (VIVS) announced the pricing of a public offering valued at up to $4 million, with an initial closing of $3 million expected to occur April 1, 2026.
The initial closing consists of common stock and pre-funded warrants priced at $1.140 per share and $1.139 per pre-funded warrant, representing 286,557 common shares and 2,345,022 pre-funded warrants. The company will also issue 3,947,369 common warrants to purchase up to 150% of the aggregate number of shares sold at the initial closing.
The common warrants carry an exercise price of $1.710 per share, are immediately exercisable, and expire five years from issuance. Pre-funded warrants have an exercise price of $0.001 per share, are immediately exercisable, and expire when fully exercised.
A second closing of $1 million is planned for the 30th day following the initial closing, subject to certain conditions including minimum closing price and average trading volume requirements. A New York-based single family office leads the subscription.
Joseph Gunnar & Co. LLC serves as the exclusive placement agent for the offering.
The securities are offered under an effective registration statement on Form S-1 filed with the Securities and Exchange Commission. The registration statement was initially filed March 27, 2026, amended March 31, 2026, and declared effective March 31, 2026.
VivoSim Labs provides pharmaceutical and biotechnology testing services using three-dimensional human tissue models for liver and intestinal toxicology. The San Diego-based company offers new approach methodologies that serve as alternatives to animal testing for drug development.